Hospital Acquired Infection (HAI) Control Markets

Feb 22, 2017
242 Pages - Pub ID: KLI15261546
Share this report
 
Online Download $4,500
Departmental Site License (one location, 10 users) $6,750
Global Site License $9,000
Hospital Acquired Infection (HAI) Control Markets

Hospital Acquired Infection (HAI) Control Markets focuses on the market for preventing, testing, and treating infections in the healthcare environment. Major consideration is given to bacterial nosocomial infections because they are the most frequent type of infections spread in the healthcare delivery setting and the practical aspects of diagnosis and therapy are more meaningful based on a combination of medical and financial considerations. The report provides a market analysis for each of three areas: prevention (sterilization and disinfection equipment), testing, and treatment, detailing the following market data:
  • The Global Market for Hospital Infection Control, 2010-2021
  • The Global Market for Hospital Infection Prevention Equipment and Consumables (Sterilization/Disinfection), 2010-2021
  • The Global Market for Hospital Infection Prevention (Sterilization/Disinfection) Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • Market Value for Infection Prevention Equipment and Related Consumables by Product Type, 2016 (Medical Device/Instrument Sterilization, Wide-Area/Room Sterilization, Medical-grade Disinfection Solutions, Other Products, Total)
  • Market Value for Infection Prevention Equipment and Related Consumables by Technology, 2016 (Heat/Steam, Gas/Chemical, Ultrasound, Other, Total)
  • The Global Market for Hospital Infection Prevention (Sterilization/Disinfection), Leading Suppliers’ Shares, Estimates for 2016
  • The Global Market for Hospital Infection Testing/Diagnostics, 2010-2021
  • The Global Market for Hospital Infection Testing/Diagnostics, Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • The Global Market for Hospital Infection Testing/Diagnostics Leading Suppliers’ Shares Estimates for 2016
  • The Global Market for Hospital Infection Treatment, 2010-2021
  • The Global Market for Hospital Infection Treatment Estimated Products, Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • The Global Market for Hospital Infection Treatment, Leading Suppliers' Shares, Estimated Share for HAIs for 2016
  • Annual Sales of Select Antibacterial Products, 2016
  • The Global Market for Hospital Infection Control, Estimated Market Share by Segment, 2016 (Treatment, Prevention, Testing)
  • The Global Market for Hospital Infection Control Estimated Market Share by Facility Setting, 2016 (Hospitals, Outpatient Servicing Centers, Dialysis Centers, Nursing Homes, Community Clinics, Others)
  • The Global Market for Hospital Infection Control Estimated Market Share by Hospital Department, 2016 (ICU, Med/Surg, Pediatrics, Others)
  • The Global Market for Hospital Infection Control, Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
  • The Global Market for Hospital Infection Control, Estimated Product Sales by Geographic Region, 2010-2021 (United States, Europe, Rest of World)
  • The Global Market for Hospital Infection Control, Estimated Market Share by Geographic Region, 2016 (%) (United States, Europe, Rest of World)
  • The Global Market for Hospital Infection Control, Estimated Market Share by Region, 2016 (%) (Developed Europe, Emerging Europe, United States, Rest of World [Japan, India, Canada, Brazil, China, Mexico, Africa, Other Developed, Other Emerging])
  • Global Markets for HAI by Participant and Segment (Infection Prevention, Infection Diagnostics, Infection Treatment)
A nosocomial infection is a new infection that develops in a patient during hospitalization or during a stay at a health facility. It is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, so infections incubating, but not clinically apparent, at admission are excluded. This type of infection is also known as a hospital-acquired infection (or, more generically, healthcare associated infection). The report provides the following data regarding nosocomial infections:
  • Frequency of the Most Common Nosocomial Infections
  • Market Value for Nosocomial Infection Diagnostics by Class, 2016 (Immunoassays, Microbial Identification / Antimicrobial Sensitivity (ID/AST), Molecular DNA, Total)
  • Market Value for Nosocomial Infection Diagnostics by Pathogen Target, 2016 (C. difficile Infections; MRSA Infections; Enterococcus, vancomycin-resistant; Enterobacteriaceae, carbapenem-resistant; M Tuberculosis; Others; Total)
  • Market Value for Nosocomial Infection Treatments by Class, 2016 (Quinolones, Glycopeptides, ß-lactamase inhibitors, Tetracyclines, Oxazolidinones, Macrolides, Carbapenems, Cephalosporins, Penicillins, Combinations, Others, Total)
  • Nosocomial Infection Drug Candidates by Class, 2016 (Quinolones, Glycopeptides, Aminoglycosides, Tetracyclines, Oxazolidinones, Macrolides, Pleuromutilins, Cephalosporins, Fabl inhibitors, Combinations, Others, Total)
  • Market Value for Nosocomial Infection Treatments by Pathogen Target, 2016 (ABSSSI, cUTI, MRSA Infections, HAP/VAP, C. Difficile Infections, Others, Total)
Hospital acquired infections share many of the challenges faced by the larger healthcare industry. Both challenges and industry trends are discussed in Hospital Acquired Infection (HAI) Control Markets, as well as market growth drivers and market growth inhibitors. One of the challenges facing the market is that increased attention to identification in the emergency department (ED) is needed to reduce risk and control exposure. With rapid identification, placing patients in isolation, whether they are colonized or infected, will likely make a difference in the resistance rates and spread of microorganisms in hospitalized patients.

The majority of competitive participation for healthcare infection control is in the United States and Europe. However, competition is steadily escalating in these areas, which is encouraging more participation in other regions such as Asia and Latin America. The report profiles important players in the current competitive landscape, including:
  • 3M
  • Abbott Laboratories
  • AbbVie
  • Advanced Sterilization Products
  • Alere
  • AstraZeneca
  • Bayer
  • Becton, Dickinson
  • Belimed
  • bioMérieux
  • Cantel Medical
  • Danaher
  • Ecolab
  • Getinge AB
  • GlaxoSmithKline
  • Merck & Co.
  • Pfizer, Inc.
  • Roche (F. Hoffman-La Roche, Ltd.)
  • Sakura Seiki, Co., Ltd.
  • Steris plc
  • TSO3
Market analysis in this report considers primarily the epidemiological considerations and the size of patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis. Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital and primary care environment in order to construct a picture of the infection prevention, testing and treatment needs.


CHAPTER ONE: EXECUTIVE SUMMARY

OVERVIEW
THE NOSOCOMIAL INFECTION

Table 1-1: Frequency of the Most Common Nosocomial Infections

MARKET SCOPE
RESEARCH METHODOLOGY
INDUSTRY CHALLENGES

Table 1-2: Growth Drivers and Inhibitors

TOTAL SIZE AND GROWTH OF THE MARKET

Table 1-3: The Global Market for Hospital Infection Control, 2010-2021

figure 1-1: Global Market for Hospital Infection Control, 2010-2021

ISSUES AND TRENDS AFFECTING MARKET

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

OVERVIEW

Introduction to Pathogens
Classification of Antibacterial Organisms

COMMON HOSPITAL (NOSOCOMIAL) INFECTIONS
DESCRIPTION OF INFECTIONS

Acinetobacter Baumannii
Clostridium Difficile
Gastroenteritis
Hospital-Acquired Pneumonia (HAP)
Pseudomonas Aeruginosa
Staphylococcus Aureus/Methicillin-Resistant Staphylococcus Aureus
Stenotrophomonas Maltophilia
Tuberculosis
Urinary Tract Infections
Vancomycin-Resistant Enterococcus
Ventilator-Associated Pneumonia (VAP)
Patient Risk Factors
General Populations at Risk for Infection

Table 2-1: Global Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region (Cancer [newly diagnosed; active treatment], Diabetes, HIV/AIDS, Surgical Procedure, ESRD/Dialysis, Organ Transplants, Cystic Fibrosis; United States, Europe, Other Regions, World)

WORLD DEMOGRAPHICS

figure 2-1: The Global Population, 2005-2050

Table 2-2: Global Population Trends Age 65+, 2000-2050

Assessing the Problem: Nosocomial Infection Statistics

figure 2-2: U.S. Hospital Admissions and Percent of Hospital Acquired Infections (HAIs) (MRSA, C. diff, Others)
figure 2-3: European Union Hospital Admissions and Percent of Hospital Acquired Infections (HAIs) (SSI, Bloodstream, MRSA, Lower RTI, UTI, Others)

Hospital Length of Stay

U.S. GOVERNMENT'S NATIONAL PLAN TO PREVENT HEALTHCARE ASSOCIATED INFECTIONS (HAIS)
STEERING COMMITTEE
EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASES
AFFORDABLE CARE ACT (ACA) FUNDING
EMERGING INFECTIONS PROGRAM

Table 2-3: U.S. States ACA HAI Prevention Infrastructure Funding Awards, 2013-2016

THE DEPARTMENT OF HEALTH AND HUMAN SERVICES: 2017 BUDGET HIGHLIGHTS

Table 2-4: U.S. Department of Health & Human Services Fiscal Budget, 2015-2017

NATIONAL HEALTHCARE SAFETY NETWORK

Table 2-5: U.S. Hospital Acquired Infection Standardized Infection Ratio (SIR), 2010-2014

figure 2-4: U.S. Hospital Acquired Infection Standardized Infection Ratio (SIR) 2012 through 2014

HEALTHCARE INFECTION SURVEILLANCE PROCESS
PHARMACEUTICAL MANUFACTURER AND MARKETER TRENDS

Trends in Partnerships and Alliances
Developers Trends

CHAPTER THREE: INFECTION PREVENTION

OVERVIEW

Table 3-1: Methods of Sterilization and Disinfection

MARKET OVERVIEW

Table 3-2: The Global Market for Hospital Infection Prevention Equipment and Consumables (Sterilization/Disinfection), 2010-2021

Healthcare Infection Prevention Market by Geographical Region

Table 3-3: The Global Market for Hospital Infection Prevention (Sterilization/Disinfection) Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)
Methods of Transmission

HIGH-RISK FACILITIES OR DEPARTMENTS

Acute Care Hospitals
Long-term Care Facilities
Outpatient Settings
Technology Overview

Table 3-4: Market Value for Infection Prevention Equipment and Related Consumables by Product Type, 2016 (Medical Device/Instrument Sterilization, Wide-Area/Room Sterilization, Medical-grade Disinfection Solutions, Other Products, Total)
Sterilization vs. Disinfection

EQUIPMENT AND SOLUTIONS

Table 3-5: Market Value for Infection Prevention Equipment and Related Consumables by Technology, 2016 (Heat/Steam, Gas/Chemical, Ultrasound, Other, Total)

HEAT/STEAM STERILIZATION

Product Examples

CHEMICAL AND GAS STERILIZATION

Disinfecting Agents and Medical Device Components
Sterilants

Table 3-6: Summary of Advantages and Disadvantages of Chemical Agents Used as Chemical Sterilants or as High-Level Disinfectants

Table 3-7: Comparison of the Characteristics of Selected Chemicals Used as High-Level Disinfectants or Chemical Sterilants

Product Examples

Mid-Level Disinfectants

Table 3-8: Comparison of the Characteristics of Selected Hospital Disinfectants for General Disinfection of Environmental Surfaces


RADIATION STERILIZATION

Product Examples

Table 3-9: Developments, Healthcare Infection Prevention


COMPETITIVE ANALYSIS

Table 3-10: The Global Market for Hospital Infection Prevention (Sterilization/Disinfection), Leading Suppliers’ Shares, Estimates for 2016

CHAPTER FOUR: INFECTION TESTING

OVERVIEW
TOTAL MARKET SIZE AND FORECAST

Table 4-1: The Global Market for Hospital Infection Testing/Diagnostics, 2010-2021

Healthcare Infection Testing Market by Geographical Region

Table 4-2: The Global Market for Hospital Infection Testing/Diagnostics, Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)

TESTING FOR NOSOCOMIAL INFECTIONS

Drug-Resistance/Susceptibility Testing
Genotypic Methods
DNA Sequencing
Solid-phase Hybridization Techniques
Microarrays
Real-time Polymerase Chain Reaction Techniques
Phenotypic Methods
Phage-based Assays
Colorimetric Methods
The Nitrate Reductase Assay
Chromogenic Testing

Table 4-3: Market Value for Nosocomial Infection Diagnostics by Class, 2016 (Immunoassays, Microbial Identification / Antimicrobial Sensitivity (ID/AST), Molecular DNA, Total)

SPECIFIC SERIOUS HEALTHCARE INFECTION TESTING

Table 4-4: Tested Samples, Pathogens Isolated by Infection Type (Surgical Site Infection [SSI], Central Line-associated Bloodstream Infections [CLABSI], Catheter-associated Urinary Tract Infections [CAUTI])

Acinetobacter Baumannii
Carbapenem-resistant Enterobacteriaceae
Clostridium Difficile
Product Examples
Hospital-Acquired Pneumonia
Pseudomonas Aeruginosa
Staphylococcus Aureus
Ventilator-Associated Pneumonia

Table 4-5: Significant Approvals for Detecting Serious Healthcare Infections

figure 4-1: HAI Test Approvals in the U.S. by Year and Type, 2000-2016 (Staph/MRSA, C. diff, Others)

figure 4-2: Distribution of Diagnostic Test Approvals with HAI Indications by Pathogen, All Approvals, 2000-2016 (MRSA, C. diff, CRE, VRE, GBS, Others)

Table 4-6: Market Value for Nosocomial Infection Diagnostics by Pathogen Target, 2016 (C. difficile Infections; MRSA Infections;
Enterococcus, vancomycin-resistant; Enterobacteriaceae, carbapenem-resistant; M Tuberculosis; Others; Total)

DEVELOPMENTS

Table 4-7: Ongoing Developments, Healthcare Infection Testing

Table 4-8: Pathogen/Infection Detection Trials by Type

COMPETITIVE ANALYSIS

Table 4-9: The Global Market for Hospital Infection Testing/Diagnostics Leading Suppliers’ Shares Estimates for 2016

CHAPTER FIVE: INFECTION TREATMENT

OVERVIEW
TOTAL MARKET SIZE AND FORECAST

Table 5-1: The Global Market for Hospital Infection Treatment, 2010-2021

Healthcare Infection Treatment Market by Geographical Region

Table 5-2: The Global Market for Hospital Infection Treatment Estimated Products, Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)

PRINCIPLES OF ANTI-BACTERIAL THERAPY

Infecting Organism
Antibiotic Sensitivity Testing
Site of Infection
Host Defenses and Organ Function
Antibiotic Pharmacokinetics
Monitoring Therapy

CLASSIFICATIONS OF ANTIBACTERIAL PRODUCTS

Aminoglycosides
Carbapenems
Cephalosporins
Glycopeptides
Macrolides
Penicillins
Quinolones
Sulfonamides
Tetracyclines

MARKET SIZE AND SALES DISTRIBUTION BY ANTIBIOTIC CLASS

Table 5-3: Market Value for Nosocomial Infection Treatments by Class, 2016 (Quinolones, Glycopeptides, ß-lactamase inhibitors, Tetracyclines, Oxazolidinones, Macrolides, Carbapenems, Cephalosporins, Penicillins, Combinations, Others, Total)

Table 5-4: Nosocomial Infection Drug Candidates by Class, 2016 (Quinolones, Glycopeptides, Aminoglycosides, Tetracyclines, Oxazolidinones, Macrolides, Pleuromutilins, Cephalosporins, Fabl inhibitors, Combinations, Others, Total)

INFECTIONS AND DRUG RESISTANCE

Easing Approvals of Antibiotics

Table 5-5: CDER NME NDAs/BLAs Filings and Approvals as of 12/9/15

QUALIFIED INFECTIOUS DISEASE PROGRAM DESIGNATIONS

Causes of Drug Resistance
Drug Resistance in Select Populations
Treatment Guidelines

Table 5-6: Antibiotics with Difficult Penetration

Table 5-7: Market Value for Nosocomial Infection Treatments by Pathogen Target, 2016 (ABSSSI, cUTI, MRSA Infections, HAP/VAP, C. Difficile Infections, Others, Total)

NEW DEVELOPMENTS

Table 5-8: New Developments, Healthcare Infection Treatments, as of December 2016

Table 5-9: Infection Treatments in Development by Phase, as of December 2016

Table 5-10: Infection Treatment Drugs in Development by Route of Administration, as of December 2016

New Developments in Biotherapies for Infection Treatment

COMPETITIVE ANALYSIS

Table 5-11: The Global Market for Hospital Infection Treatment, Leading Suppliers' Shares, Estimated Share for HAIs for 2016

Table 5-12: Select Treatment Options for Serious Bacterial Infections (Type, Brand, and Manufacturer)

Leading Products

Table 5-13: Annual Sales of Select Antibacterial Products, 2016

CHAPTER SIX: MARKET OPPORTUNITIES FOR HOSPITAL INFECTION CONTROL


MARKET CONSIDERATIONS
MARKET OVERVIEW

Table 6-1: The Global Market for Hospital Infection Control, 2010-2021

figure 6-1: The Global Market for Hospital Infection Control, 2010-2021

figure 6-2: The Global Market for Hospital Infection Control, Estimated Market Share by Segment, 2016 (Treatment, Prevention, Testing)

Healthcare-Acquired Infection Distribution by Setting

figure 6-3: The Global Market for Hospital Infection Control Estimated Market Share by Facility Setting, 2016 (Hospitals, Outpatient

Servicing Centers, Dialysis Centers, Nursing Homes, Community Clinics, Others)

figure 6-4: The Global Market for Hospital Infection Control Estimated Market Share by Hospital Department, 2016 (ICU, Med/Surg, Pediatrics, Others)

Healthcare Infection Control Market by Geographical Region

Table 6-2: The Global Market for Hospital Infection Control, Estimated Products Sales by Primary Geographic Region, 2010-2021 (United States, Europe, Rest of World, Total)

figure 6-5: The Global Market for Hospital Infection Control, Estimated Product Sales by Geographic Region, 2010-2021 (United States, Europe, Rest of World)

figure 6-6: The Global Market for Hospital Infection Control, Estimated Market Share by Geographic Region, 2016 (%) (United States, Europe, Rest of World)

Developed and Emerging Market Analysis

Table 6-3: Developed vs. Emerging Markets

figure 6-7: The Global Market for Hospital Infection Control, Estimated Market Share by Region, 2016 (%) (Developed Europe, Emerging Europe, United States, Rest of World [Japan, India, Canada, Brazil, China, Mexico, Africa, Other Developed, Other Emerging])

CHAPTER SEVEN: COMPANY PROFILES


INTRODUCTION

figure 7-1: Global Markets for HAI by Participant and Segment (Infection Prevention, Infection Diagnostics, Infection Treatment)

3M

Table 7-1: 3M Company Corporate Summary
Company Overview
Company Performance

ABBOTT LABORATORIES

Table 7-2: Abbott Laboratories Corporate Summary
Company Overview
Company Performance

ABBVIE

Table 7-3: AbbVie Corporate Summary
Company Overview
Company Performance

ADVANCED STERILIZATION PRODUCTS

Table 7-4: Advanced Sterilization Products Corporate Summary
Company Overview
Company Performance

ALERE

Table 7-5: Alere Corporate Summary
Company Overview
Company Performance

ASTRAZENECA

Table 7-6: AstraZeneca Corporate Summary
Company Overview
Company Performance

BAYER

Table 7-7: Bayer Corporate Summary
Company Overview
Company Performance

BECTON, DICKINSON AND COMPANY

Table 7-8: Becton, Dickinson Corporate Summary
Company Overview
Company Performance

BELIMED

Table 7-9: Belimed Corporate Summary
Company Overview
Company Performance

BIOMÉRIEUX S.A.

Table 7-10: bioMérieux Corporate Summary
Company Overview
Company Performance

CANTEL MEDICAL CORP.

Table 7-11: Cantel Medical Corporate Summary
Company Overview
Company Performance

DANAHER CORPORATION

Table 7-12: Danaher Corporate Summary
Company Overview
Company Performance

ECOLAB, INC.

Table 7-13: Ecolab Corporate Summary
Company Overview
Company Performance

GETINGE GROUP

Table 7-14: Getinge AB Corporate Summary
Company Overview
Company Performance

GLAXOSMITHKLINE PLC

Table 7-15: GlaxoSmithKline Corporate Summary
Company Overview
Company Performance

MERCK & CO.

Table 7-16: Merck Corporate Summary
Company Overview
Company Performance

PFIZER, INC.

Table 7-17: Pfizer Corporate Summary
Company Overview
Company Performance

ROCHE

Table 7-18: F. Hoffman-La Roche, Ltd. Corporate Summary
Company Overview
Company Performance

SAKURA SEIKI CO., LTD.

Table 7-19: Sakura Seiki Corporate Summary
Company Overview

STERIS PLC

Table 7-20: Steris Corporate Summary
Company Overview
Company Performance

TSO3, INC.

Table 7-21: TSO3 Corporate Summary
Company Overview
Company Performance

APPENDIX: LIST OF PARTICIPANTS

Table A-1: List of Participants

In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.